TVTX Stock Overview
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Travere Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.80 |
| 52 Week High | US$22.75 |
| 52 Week Low | US$5.25 |
| Beta | 0.61 |
| 1 Month Change | -22.46% |
| 3 Month Change | -33.64% |
| 1 Year Change | -72.17% |
| 3 Year Change | -76.75% |
| 5 Year Change | -70.06% |
| Change since IPO | 12.62% |
Recent News & Updates
Recent updates
Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing
Apr 11Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 07Travere Therapeutics: Tarpeyo's Approval Is Good News
Jan 31Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Oct 07Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
Aug 30Travere: Setback Presents Cautious Opportunity
Jul 18Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Jul 09Could The Travere Therapeutics, Inc. (NASDAQ:TVTX) Ownership Structure Tell Us Something Useful?
Mar 04Shareholder Returns
| TVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.3% | -4.7% | -3.7% |
| 1Y | -72.2% | -2.7% | 20.2% |
Return vs Industry: TVTX underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: TVTX underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| TVTX volatility | |
|---|---|
| TVTX Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TVTX's share price has been volatile over the past 3 months.
Volatility Over Time: TVTX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 380 | Eric Dube | www.travere.com |
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company’s clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
Travere Therapeutics, Inc. Fundamentals Summary
| TVTX fundamental statistics | |
|---|---|
| Market cap | US$441.43m |
| Earnings (TTM) | -US$376.33m |
| Revenue (TTM) | US$145.24m |
3.0x
P/S Ratio-1.2x
P/E RatioIs TVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TVTX income statement (TTM) | |
|---|---|
| Revenue | US$145.24m |
| Cost of Revenue | US$256.44m |
| Gross Profit | -US$111.20m |
| Other Expenses | US$265.13m |
| Earnings | -US$376.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.94 |
| Gross Margin | -76.57% |
| Net Profit Margin | -259.11% |
| Debt/Equity Ratio | 187.9% |
How did TVTX perform over the long term?
See historical performance and comparison